This website uses cookies in order to improve our services. If you proceed visiting this website you accept the usage of cookies. For more info please read our Data Privacy statement.

 

Kidney Cancer NGS Panels


General Cancer Testing | Brain & CNS Cancer | Breast & Ovarian Cancer | Colorectal & Prostate Cancer | Endocrine & Thyroid Cancer | Gastric Cancer | Hematologic Cancer | Kidney Cancer | Lung Cancer | Pancreatic Cancer | Skin Cancer & Melanoma | Solid Tumors | Less Common Cancers


Kidney cancer is also known as renal cancer. The most common types of renal cancers are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC). 

Inherited kidney cancers occur in about 5% of the cases. Genetic syndromes that can be related to increased risk to develop kidney cancer are: Von Hippel-Lindau syndrome (VHL), hereditary non-VHL clear cell renal cell carcinoma, hereditary papillary renal cell carcinoma (HPRCC), Birt-Hogg-Dubé syndrome (BHD), hereditary leiomyomatosis and renal cell carcinoma (HLRCC), and tuberous sclerosis complex (TSC) (Source: Cancer.net).

On this page NGS panel that target genes wherein mutations are related to elevated risk for developing kidney cancers are listed. Genes that are included in some of these NGS panels are the BAP1, PTEN, SDHB, SDHC, SDHD, TP53, and VHL genes.

For more information on the targeted genes please contact the NGS panel provider, general information on kidney cancer are found on this website.


Kidney Cancer

Invitae Renal/Urinary Tract Cancers Panel

The Invitae Renal/Urinary Tract Cancers Panel analyzes up to 29 genes associated with an increased lifetime risk of developing cancers of the urinary tract (kidneys, renal pelvis, ureters, bladder, and urethra). These genes were selected based on the available evidence to date to provide Invitae’s most comprehensive panel for hereditary renal/urinary tract cancers. Many of these genes are also associated with an increased risk of other cancer types.
Source: Invitae

RENALNEXT

RenalNext is a next generation sequencing (NGS) panel that simultaneously analyzes 19 genes associated with increased risk for kidney cancer.
Ambry utilizes NGS to offer a comprehensive hereditary kidney cancer panel. Genes on this panel include BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL. Full gene sequencing is performed for 18 of the genes (excluding EPCAM). For MITF, only the status of the c.952G>A (p.E318K) alteration is analyzed and reported. Gross deletion/duplication analysis is performed for 18 genes (excluding MITF).
Source: Ambry Genetics

Renal Cancer

Multi Gene Panel (16 Genes)
Targeted genes: BAP1 CHEK2 FH FLCN GPC3 MET PTEN SDHB SDHC SDHD SMARCB1 TP53 TSC1 TSC2 VHL WT1
Source: Medical Genetics Center

RENAL CANCER NEXTGEN SEQUENCING (NGS) PANEL

Renal cell carcinoma is the most common type of kidney cancer and includes many subtypes such as clear cell, papillary, chromophobe, and oncocytoma accounting for approximately 75%, 12%, 5% and 4% of cases.
The renal cancer next generation sequencing panel assesses genes (CDC73, FH, FLCN, MET, MLH1, MSH2, MSH6, PMS2, PTEN, SDHB, SDHC, SDHD, SMARCB1, TP53, TSC1, TSC2, VHL, WT1) that have been shown to be causative when mutated for disorders that have renal cancer as a clinical feature.
Source: Prevention Genetics

Renal Cancer Panel

The family history is suggestive of a predisposition to renal cancer. Although VHL, MET, FLCN, FH, TSC1 and TSC2 are the genes that are the most often associated with classic forms of hereditary renal cancer, there are several other genes that cause an increased risk of renal cancer. Tested genes: BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL

Source: GeneDx

Renal cancer panel, targeted

tested genes EPCAM, FH, FLCN, HNF1A, HNF1B, MET, MITF, MLH1, MSH2, MSH6, PMS1, PMS2, PTEN, SDHB, SDHD, TSC1, TSC2, VHL, WT1

Source: Centogene

Renal Cancer: Sequencing Panel

Renal cancer is a multifarious and heterogeneous disease with a varied spectrum of malignant subtypes and clinical presentation. A number of gene mutations have been reported in the literature. Renal cell carcinoma (RCC) tumor subtypes include clear cell or conventional (70-80%); papillary type 1 and type 2 (10-15%); chromophobe (3-5%) and collecting duct (1%). The general population's lifetime risk to develop RCC is 1.5%. RCC is the seventh and eighth most common cancer in men and women respectively.
Targeted genes: BAP1, BUB1B, CDC73, CDKN1C, FH, FLCN, GPC3, MET, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, SDHB, SDHC, SDHD, SMARCB1, TP53, TSC1, TSC2, VHL, WT1
Source: Emory Genetics Laboratory

Renal Hereditary Cancer Panel

Sequencing and Deletion/Duplication, 15 Genes
Source: Arup Laboratories


Pin It